Skeletal muscle wasting and long-term prognosis in patients undergoing rectal cancer surgery without neoadjuvant therapy
BACKGROUND: Derangement of body composition has been associated with dismal long-term survival in several gastrointestinal cancers including rectal tumors treated with neoadjuvant therapies. The role of specific preoperative anthropometric indexes on the oncologic outcomes of patients undergoing upf...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8881874/ https://www.ncbi.nlm.nih.gov/pubmed/35216606 http://dx.doi.org/10.1186/s12957-021-02460-7 |
_version_ | 1784659574858448896 |
---|---|
author | Giani, Alessandro Famularo, Simone Fogliati, Alessandro Riva, Luca Tamini, Nicolò Ippolito, Davide Nespoli, Luca Braga, Marco Gianotti, Luca |
author_facet | Giani, Alessandro Famularo, Simone Fogliati, Alessandro Riva, Luca Tamini, Nicolò Ippolito, Davide Nespoli, Luca Braga, Marco Gianotti, Luca |
author_sort | Giani, Alessandro |
collection | PubMed |
description | BACKGROUND: Derangement of body composition has been associated with dismal long-term survival in several gastrointestinal cancers including rectal tumors treated with neoadjuvant therapies. The role of specific preoperative anthropometric indexes on the oncologic outcomes of patients undergoing upfront surgery for rectal cancer has not been investigated. The aim of the study is to evaluate the association of body composition and overall survival in this specific cohort. METHODS: Lumbar computed tomography images, obtained within the 30 days previous to surgery, between January 2009 and December 2016, were used to calculate population-specific thresholds of muscle mass (sarcopenia), subcutaneous and visceral adiposity, visceral obesity, sarcopenic obesity, and myosteatosis. These body composition variables were related with overall survival (OS), tumor-specific survival (TSS), and disease-free survival (DFS). OS, TSS, and DFS were evaluated by the Kaplan-Meier method. Cox regression analysis was used to identify independent predictors of mortality, tumor-specific mortality, and recurrence, and data were presented as hazard ratio (HR) and 95% confidence interval (CI). RESULTS: During the study period, 411 patients underwent rectal resection for cancer, and among these, 129 were without neoadjuvant chemoradiation. The median follow-up was 96.7 months. At the end of the follow-up, 41 patients (31.8%) had died; of these, 26 (20.1%) died for tumor-related reasons, and 36 (27.1%) experienced disease recurrence. One-, three-, and five-year OS was 95.7%, 86.0%, and 76.8% for non-sarcopenic patients versus 82.4%, 58.8%, and 40.0% for sarcopenic ones respectively (p < 0.001). Kaplan-Meier survival curves comparing sarcopenic and non-sarcopenic patients showed a significant difference in terms of OS (log-rank < 0.0001). Through multivariate Cox regression, overall mortality risk was associated only with sarcopenia (HR 1.96; 95%CI 1.03–3.74; p = 0.041). Disease stage IV and III (HR 13.75; 95% CI 2.89–65.6; p < 0.001 and HR 4.72; 95% CI 1.06–21.1; p = 0.043, respectively) and sarcopenia (HR 2.62; 95% CI 1.22–5.6; p = 0.013) were independently associated with TSS. The other body composition indexes investigated showed no significant association with prognosis. CONCLUSIONS: These results support the inclusion of body composition assessment for prognostic stratification of rectal cancer patients undergoing upfront resection. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12957-021-02460-7. |
format | Online Article Text |
id | pubmed-8881874 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-88818742022-02-28 Skeletal muscle wasting and long-term prognosis in patients undergoing rectal cancer surgery without neoadjuvant therapy Giani, Alessandro Famularo, Simone Fogliati, Alessandro Riva, Luca Tamini, Nicolò Ippolito, Davide Nespoli, Luca Braga, Marco Gianotti, Luca World J Surg Oncol Research BACKGROUND: Derangement of body composition has been associated with dismal long-term survival in several gastrointestinal cancers including rectal tumors treated with neoadjuvant therapies. The role of specific preoperative anthropometric indexes on the oncologic outcomes of patients undergoing upfront surgery for rectal cancer has not been investigated. The aim of the study is to evaluate the association of body composition and overall survival in this specific cohort. METHODS: Lumbar computed tomography images, obtained within the 30 days previous to surgery, between January 2009 and December 2016, were used to calculate population-specific thresholds of muscle mass (sarcopenia), subcutaneous and visceral adiposity, visceral obesity, sarcopenic obesity, and myosteatosis. These body composition variables were related with overall survival (OS), tumor-specific survival (TSS), and disease-free survival (DFS). OS, TSS, and DFS were evaluated by the Kaplan-Meier method. Cox regression analysis was used to identify independent predictors of mortality, tumor-specific mortality, and recurrence, and data were presented as hazard ratio (HR) and 95% confidence interval (CI). RESULTS: During the study period, 411 patients underwent rectal resection for cancer, and among these, 129 were without neoadjuvant chemoradiation. The median follow-up was 96.7 months. At the end of the follow-up, 41 patients (31.8%) had died; of these, 26 (20.1%) died for tumor-related reasons, and 36 (27.1%) experienced disease recurrence. One-, three-, and five-year OS was 95.7%, 86.0%, and 76.8% for non-sarcopenic patients versus 82.4%, 58.8%, and 40.0% for sarcopenic ones respectively (p < 0.001). Kaplan-Meier survival curves comparing sarcopenic and non-sarcopenic patients showed a significant difference in terms of OS (log-rank < 0.0001). Through multivariate Cox regression, overall mortality risk was associated only with sarcopenia (HR 1.96; 95%CI 1.03–3.74; p = 0.041). Disease stage IV and III (HR 13.75; 95% CI 2.89–65.6; p < 0.001 and HR 4.72; 95% CI 1.06–21.1; p = 0.043, respectively) and sarcopenia (HR 2.62; 95% CI 1.22–5.6; p = 0.013) were independently associated with TSS. The other body composition indexes investigated showed no significant association with prognosis. CONCLUSIONS: These results support the inclusion of body composition assessment for prognostic stratification of rectal cancer patients undergoing upfront resection. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12957-021-02460-7. BioMed Central 2022-02-25 /pmc/articles/PMC8881874/ /pubmed/35216606 http://dx.doi.org/10.1186/s12957-021-02460-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Giani, Alessandro Famularo, Simone Fogliati, Alessandro Riva, Luca Tamini, Nicolò Ippolito, Davide Nespoli, Luca Braga, Marco Gianotti, Luca Skeletal muscle wasting and long-term prognosis in patients undergoing rectal cancer surgery without neoadjuvant therapy |
title | Skeletal muscle wasting and long-term prognosis in patients undergoing rectal cancer surgery without neoadjuvant therapy |
title_full | Skeletal muscle wasting and long-term prognosis in patients undergoing rectal cancer surgery without neoadjuvant therapy |
title_fullStr | Skeletal muscle wasting and long-term prognosis in patients undergoing rectal cancer surgery without neoadjuvant therapy |
title_full_unstemmed | Skeletal muscle wasting and long-term prognosis in patients undergoing rectal cancer surgery without neoadjuvant therapy |
title_short | Skeletal muscle wasting and long-term prognosis in patients undergoing rectal cancer surgery without neoadjuvant therapy |
title_sort | skeletal muscle wasting and long-term prognosis in patients undergoing rectal cancer surgery without neoadjuvant therapy |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8881874/ https://www.ncbi.nlm.nih.gov/pubmed/35216606 http://dx.doi.org/10.1186/s12957-021-02460-7 |
work_keys_str_mv | AT gianialessandro skeletalmusclewastingandlongtermprognosisinpatientsundergoingrectalcancersurgerywithoutneoadjuvanttherapy AT famularosimone skeletalmusclewastingandlongtermprognosisinpatientsundergoingrectalcancersurgerywithoutneoadjuvanttherapy AT fogliatialessandro skeletalmusclewastingandlongtermprognosisinpatientsundergoingrectalcancersurgerywithoutneoadjuvanttherapy AT rivaluca skeletalmusclewastingandlongtermprognosisinpatientsundergoingrectalcancersurgerywithoutneoadjuvanttherapy AT tamininicolo skeletalmusclewastingandlongtermprognosisinpatientsundergoingrectalcancersurgerywithoutneoadjuvanttherapy AT ippolitodavide skeletalmusclewastingandlongtermprognosisinpatientsundergoingrectalcancersurgerywithoutneoadjuvanttherapy AT nespoliluca skeletalmusclewastingandlongtermprognosisinpatientsundergoingrectalcancersurgerywithoutneoadjuvanttherapy AT bragamarco skeletalmusclewastingandlongtermprognosisinpatientsundergoingrectalcancersurgerywithoutneoadjuvanttherapy AT gianottiluca skeletalmusclewastingandlongtermprognosisinpatientsundergoingrectalcancersurgerywithoutneoadjuvanttherapy |